CONTEXT: Dropout rates in randomized clinical trials of antipsychotic drugs have consistently been reported to be high, and the use of a placebo-controlled design is hypothesized to be one of the reasons for this. OBJECTIVE: To investigate this hypothesis in a meta-analysis of available data from pertinent clinical trials. DATA SOURCES: Comprehensive search of PubMed- and MEDLINE-listed journals. STUDY SELECTION: Double-blind randomized controlled clinical trials of the second-generation antipsychotics risperidone, olanzapine, quetiapine, amisulpride, ziprasidone, and aripiprazole meeting the following criteria: unselected patient population with a diagnosis of schizophrenia or schizoaffective disorder, change in psychopathologic symptoms as the primary end point, and trial duration of 12 weeks or less. DATA EXTRACTION: Sample size, mean age, baseline disease severity, dropout rate, trial design, trial duration, and publication year. DATA SYNTHESIS: Thirty-one trials meeting the inclusion criteria were found, comprising 10 058 subjects. Weighted mean dropout rates in the active treatment arms were significantly higher in placebo-controlled trials (PCTs) than in active-control trials: 48.1% (PCTs) vs 28.3% (active-control trials) for second-generation antipsychotics (odds ratio, 2.34; 95% confidence interval, 1.58-3.47) and 55.4% (PCTs) vs 37.2% (active-control trials) for classical antipsychotics (odds ratio, 2.10; 95% confidence interval, 1.29-3.40). Within PCTs, attrition rates were significantly higher in the placebo arms than with second-generation antipsychotics (60.2% vs 48.1%; odds ratio, 1.63; 95% confidence interval, 1.37-1.94). Within the subset of trials in which both second-generation and classical antipsychotics were used, dropout rates were significantly higher with classical antipsychotics. CONCLUSIONS: Use of a placebo-controlled design had a major effect on the dropout rates observed. Because high dropout rates affect the generalizability of such studies, it is suggested that, in addition to the PCTs, studies with alternative designs need to be considered when evaluating an antipsychotic's clinical profile.
CONTEXT: Dropout rates in randomized clinical trials of antipsychotic drugs have consistently been reported to be high, and the use of a placebo-controlled design is hypothesized to be one of the reasons for this. OBJECTIVE: To investigate this hypothesis in a meta-analysis of available data from pertinent clinical trials. DATA SOURCES: Comprehensive search of PubMed- and MEDLINE-listed journals. STUDY SELECTION: Double-blind randomized controlled clinical trials of the second-generation antipsychotics risperidone, olanzapine, quetiapine, amisulpride, ziprasidone, and aripiprazole meeting the following criteria: unselected patient population with a diagnosis of schizophrenia or schizoaffective disorder, change in psychopathologic symptoms as the primary end point, and trial duration of 12 weeks or less. DATA EXTRACTION: Sample size, mean age, baseline disease severity, dropout rate, trial design, trial duration, and publication year. DATA SYNTHESIS: Thirty-one trials meeting the inclusion criteria were found, comprising 10 058 subjects. Weighted mean dropout rates in the active treatment arms were significantly higher in placebo-controlled trials (PCTs) than in active-control trials: 48.1% (PCTs) vs 28.3% (active-control trials) for second-generation antipsychotics (odds ratio, 2.34; 95% confidence interval, 1.58-3.47) and 55.4% (PCTs) vs 37.2% (active-control trials) for classical antipsychotics (odds ratio, 2.10; 95% confidence interval, 1.29-3.40). Within PCTs, attrition rates were significantly higher in the placebo arms than with second-generation antipsychotics (60.2% vs 48.1%; odds ratio, 1.63; 95% confidence interval, 1.37-1.94). Within the subset of trials in which both second-generation and classical antipsychotics were used, dropout rates were significantly higher with classical antipsychotics. CONCLUSIONS: Use of a placebo-controlled design had a major effect on the dropout rates observed. Because high dropout rates affect the generalizability of such studies, it is suggested that, in addition to the PCTs, studies with alternative designs need to be considered when evaluating an antipsychotic's clinical profile.
Authors: Robert P McMahon; Deanna L Kelly; Douglas L Boggs; Lan Li; Qiaoyan Hu; John M Davis; William T Carpenter Journal: Schizophr Bull Date: 2008-01-08 Impact factor: 9.306
Authors: Roderick J Little; Ralph D'Agostino; Michael L Cohen; Kay Dickersin; Scott S Emerson; John T Farrar; Constantine Frangakis; Joseph W Hogan; Geert Molenberghs; Susan A Murphy; James D Neaton; Andrea Rotnitzky; Daniel Scharfstein; Weichung J Shih; Jay P Siegel; Hal Stern Journal: N Engl J Med Date: 2012-10-04 Impact factor: 91.245
Authors: Haya Ascher-Svanum; Baojin Zhu; Douglas E Faries; Jonathan P Lacro; Christian R Dolder; Xiaomei Peng Journal: Patient Prefer Adherence Date: 2008-02-02 Impact factor: 2.711